複雑性尿路感染症に対するImipenem/Cilastatin sodiumの臨床効果について : 特に先行薬剤無効例に対する検討

Abstract

17歳から82歳までの45例の先行薬剤無効の複雑性尿路感染症症例に対し, IPM/CSを0.5 g×2/日, 5日間投与を行い, その薬剤効果を検討した.薬剤投与による起炎菌の消失率をみると, グラム陽性菌では79%に, 陰性菌では94%にみられた.総合臨床効果についてみると著効は8例, 有効は31例にみられ, 有効率87%であった.副作用は6例にみられたが, いずれも軽微であった

Clinical efficacy of sodium imipenem/cilastatin was studied on 45 patients with complicated urinary tract infections, on whom prior antimicrobial agents were ineffective. A 0.5g dose of IPM/CS was administered by drop infusion twice a day for 5 days. The clinical efficacy was evaluated according to the criteria of the Japanese UTI committee. Of a total of 65 strains, 29 strains of gram positive bacteria and 36 strains of gram negative bacteria, were detected as causative microbials. Bacteriologically, 23 strains of gram positive bacteria (79%) and 34 strains of gram negative bacteria (94%) were eradicated following the treatment. S. aureus, E. faecalis and Flavobacterium sp. were less sensitive to IPM/CS. Overall clinical effectiveness rate of IPM/CS in the present study was 87%. Adverse drug side effects were observed in six patients, namely they were eruption, headache and slight elevation of serum transaminase. These findings suggest that IPM/CS is an effective agent for the treatment of complicated UTI even when the prior medicine was ineffective.